The image of Donald Trump signing an executive order to expand access to psychedelic treatments, with podcaster Joe Rogan looking on, marks a curious milestone in American drug policy. What was once the fringe interest of the 1960s counterculture has found an unexpected home within the modern Republican Party. This shift is less about a sudden embrace of hallucinogenic exploration and more about a pragmatic, populist response to the deepening crisis in veteran mental health.
For years, the GOP was the primary architect of the "War on Drugs," emphasizing strict prohibition and carceral solutions. However, a growing cohort of conservative lawmakers has begun to view substances like psilocybin and MDMA through a different lens: as essential tools for treating post-traumatic stress disorder and treatment-resistant depression. By framing psychedelics as a "right to try" issue for those who have served in the military, Republicans have successfully decoupled these substances from their historical connotations.
Yet, this embrace carries an inherent tension. The party’s move toward deregulating psychedelic medicine sits uncomfortably alongside its traditional "law and order" platform. This policy pivot suggests a new, libertarian-leaning strain of conservatism that prioritizes individual medical autonomy—and perhaps a certain brand of anti-establishment skepticism—over federal drug scheduling. As the executive order takes effect, the challenge will be reconciling this newfound medical liberalism with the party's historical stance on controlled substances.
With reporting from STAT News.
Source · STAT News (Biotech)
